Research programme: bi-specific antibody therapeutics - Eli Lilly/Zymeworks

Drug Profile

Research programme: bi-specific antibody therapeutics - Eli Lilly/Zymeworks

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Jun 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 22 Oct 2014 ImClone (Eli Lilly) expands its collaboration with Zymeworks for bi-specific antibody therapeutics
  • 09 Jan 2014 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top